Research Article| Volume 103, ISSUE 2, P292-297, February 2014

Download started.


Effectiveness of combined therapy with angiotensin-converting enzyme inhibitors and statins in reducing mortality in diabetic patients with critical limb ischemia: An observational study

Published:February 03, 2014DOI:



      To investigate the effect of combined treatment with angiotensin-converting enzyme inhibitors (ACE) and statins on mortality in diabetic patients with critical limb ischemia (CLI).


      Prospective observational study of 553 consecutive diabetic patients admitted because of CLI followed for a mean of 2.2 years. All patients underwent peripheral revascularization and antithrombotic therapy was prescribed or continued and therapy with statin and ACE was recorded. Mortality from any cause was assessed and Kaplan–Meier analyses were performed to compare the relationship between survival and recorded variables.


      One hundred thirty-nine patients did not have therapy with statin or an ACE, 78 had therapy with statin without ACE, 164 had therapy with ACE without statin and 172 patients had therapy with both statin and ACE. One hundred thirty-six patients died, 45/139 with neither statin nor ACE, 40/164 with ACE only, 26/78 with statin only, and 25/172 with both statin and ACE. Multivariate analysis confirmed the independent role of age, history of stroke, renal insufficiency and dialysis. Combined treatment with ACE and statin appeared to have a protective role.


      In patients with diabetes and CLI mortality after two years is high. Life expectancy was better in patients receiving combined therapy with ACE and statin but not with therapy with only a statin or an ACE.



      CLI (critical limb ischemia), PAD (peripheral arterial disease), TASC (TransAtlantic intersociety Consensus), ACE (angiotensin-converting enzyme inhibitors), HbA1c (glycated hemoglobin), LDL (low-density lipoprotein cholesterol), HDL (high-density lipoprotein cholesterol), ANOVA (analysis of variance), OR (odds ratio), CI (confidence interval)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Diabetes Research and Clinical Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Dosluoglu H.H.
        • Lall P.
        • Harris L.M.
        • Dryjski M.L.
        Long-term limb salvage and survival after endovascular and open revascularization for critical limb ischemia after adoption of endovascular-first approach by vascular surgeons.
        J Vasc Surg. 2012; 56: 361-371
        • Leibson C.L.
        • Ransom J.E.
        • Olson W.
        • Zimmerman B.R.
        • O’fallon W.M.
        • Palumbo P.J.
        Peripheral arterial disease, diabetes, and mortality.
        Diabetes Care. 2004; 27: 2843-2849
        • Uccioli L.
        • Gandini R.
        • Giurato L.
        • Fabiano S.
        • Pampana E.
        • Spallone V.
        • et al.
        Long-term outcomes of diabetic patients with critical limb ischemia followed in a tertiary referral diabetic foot clinic.
        Diabetes Care. 2010; 33: 977-982
        • Abou-Zamzam Jr., A.M
        • Gomez N.R.
        • Molkara A.
        • Banta J.E.
        • Teruya T.H.
        • Killeen J.D.
        • et al.
        A prospective analysis of critical limb ischemia: factors leading to major primary amputation versus revascularization.
        Ann Vasc Surg. 2007; 21: 458-463
        • Young M.J.
        • McCardle J.E.
        • Randall L.E.
        • Barclay J.I.
        Improved survival of diabetic foot ulcer patients 1995–2008: possible impact of aggressive cardiovascular risk management.
        Diabetes Care. 2008; 31: 2143-2147
        • Hiatt W.R.
        Medical treatment of peripheral arterial disease and claudication.
        N Engl J Med. 2001; 344: 1608-1621
        • Feringa H.H.
        • Karagiannis S.E.
        • Vidakovic R.
        Glycemic control, lipid-lowering treatment, and prognosis in diabetic patients with peripheral atherosclerotic disease.
        Ann Vasc Surg. 2007; 21: 780-789
        • Flu H.C.
        • Lardenoye J.H.
        • Veen E.J.
        • Aquarius A.E.
        • Van Berge Henegouwen D.P.
        • Hamming J.F.
        Morbidity and mortality caused by cardiac adverse events after revascularization for critical limb ischemia.
        Ann Vasc Surg. 2009; 23: 583-597
        • Faglia E.
        • Clerici G.
        • Caminiti M.
        • Quarantiello A.
        • Curci V.
        • Morabito A.
        Advantages of myocardial revascularization after admission for critical limb ischemia in diabetic patients with coronary artery disease: data of a cohort of 564 consecutive patients.
        J Cardiovasc Med. 2008; 9: 1030-1036
        • Norgren L.
        • Hiatt W.R.
        • Dormandy J.A.
        • Nehler M.R.
        • Harris K.A.
        • Fowkes F.G.
        • on behalf of the TASC II Working Group
        Inter-society consensus for the management of peripheral arterial disease (TASC II).
        Eur J Vasc Endovasc Surg. 2007; 33: 19
        • Management of peripheral arterial disease (PAD)
        TransAtlantic Inter-Society Consensus (TASC).
        Eur J Vasc Endovasc Surg. 2000; 19 (Si-xxviii, S1–250)
        • Apelqvist J.
        • Larsson J.
        • Agardh C.D.
        Long-term prognosis for diabetic patients with foot ulcers.
        J Intern Med. 1993; 233: 485-491
        • Winkley K.
        • Stahl D.
        • Chalder T.
        • Edmonds M.E.
        • Ismail K.
        Risk factors associated with adverse outcomes in a population-based prospective cohort study of people with their first diabetic foot ulcer.
        J Diabetes Complications. 2007; 21: 341-349
        • Pinto A.
        • Tuttolomondo A.
        • Di Raimondo D.
        • Fernandez P.
        • La Placa S.
        • Di Gati M.
        • et al.
        Cardiovascular risk profile and morbidity in subjects affected by type 2 diabetes mellitus with and without diabetic foot.
        Metabolism. 2008; 57: 676-682
        • Dick F.
        • Ricco J.B.
        • Davies A.H.
        • Cao P.
        • Setacci C.
        • de Donato G.
        • et al.
        Follow-up after revascularisation.
        Eur J Vasc Endovasc Surg. 2011; 42: S75-S90
        • Diehm N.
        • Schmidli J.
        • Setacci C.
        • Ricco J.B.
        • de Donato G.
        • Becker F.
        • et al.
        Chapter III: Management of cardiovascular risk factors and medical therapy.
        Eur J Vasc Endovasc Surg. 2011; 42: S33-S42
        • ESC Guidelines on the diagnosis and treatment of peripheral artery diseases
        Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries.
        Eur Heart J. 2011; 32: 2851-2906
        • Olin J.W.
        • Allie D.E.
        • Belkin M.
        • Bonow R.O.
        • Casey Jr., D.E.
        • Creager M.A.
        • et al.
        Performance measures for adults with peripheral artery disease: a report of the American College of Cardiology.
        J Am Coll Cardiol. 2010; 56: 2147-2181
        • Feringa H.H.
        • van Waning V.H.
        • Bax J.J.
        • Elhendy A.
        • Boersma E.
        • Schouten O.
        • et al.
        Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease.
        J Am Coll Cardiol. 2006; 47: 1182-1187
        • Aiello F.A.
        • Khan A.A.
        • Meltzer A.J.
        • Gallagher K.A.
        • McKinsey J.F.
        • Schneider D.B.
        Statin therapy is associated with superior clinical outcomes after endovascular treatment of critical limb ischemia.
        J Vasc Surg. 2012; 55: 371-379
        • Heart Outcomes Prevention Evaluation Study Investigators
        Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
        N Engl J Med. 2000; 342: 145-153
        • Chi Y.W.
        • Jaff M.R.
        Optimal risk factor modification and medical management of the patient with peripheral arterial disease.
        Catheter Cardiovasc Interv. 2008; 71: 475-489
        • Nanjundappa A.
        • Dieter R.S.
        Pharmacological interventions on critical limb ischemia in diabetic patients.
        J Cardiovasc Surg. 2012; 53: 39-43
        • Brown L.C.
        • Johnson J.A.
        • Majumdar S.R.
        • Tsuyuki R.T.
        • McAlister F.A.
        Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis.
        CMAJ. 2004; 171: 1189-1192
        • Parekh N.
        • Nanjundappa A.
        • Dieter R.S.
        Pharmacological interventions on critical limb ischemia in diabetic patients.
        J Cardiovasc Surg. 2012; 53: 39-43
        • Yusuf S.
        • Sleight P.
        • Pogue J.
        • Bosch J.
        • Davies R.
        • Dagenais G.
        Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
        N Engl J Med. 2000; 342: 145-153
        • Hirsch A.T.
        • Duprez D.
        The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease.
        Vasc Med. 2003; 8: 273-278
        • American Diabetes Association
        Standards of Medical Care in diabetes-2012.
        Diabetes Care. 2012; 35
        • Tkác I.
        Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: overview and metanalysis of five trials.
        Diabetes Res Clin Pract. 2009; 86: S57-S62